EPCAM and ovarian carcinoma: These findings collectively emphasize the necessity for continued research into EpCAM-focused therapies, aiming at disrupting the intricate mechanisms through which EpCAM+ cells contribute to ovarian cancer’s malignancy and chemoresistance, thereby opening avenues for more effective and personalized treatment modalities for EOC [64, 67, 68].